Litcius/Paper detail

Chimeric antigen receptor‐modified macrophages trigger systemic anti‐tumour immunity

Zhiyuan Niu, Guanxu Chen, Wei Chun Chang, Pengyang Sun, Zhixia Luo, Huiyong Zhang, Lingtong Zhi, Changjiang Guo, Han Chen, Meichen Yin, Wuling Zhu

2020The Journal of Pathology121 citationsDOI

Abstract

Abstract Preliminary results and emerging data have shown that lipid droplet high (LD hi ) immunosuppressive cells accumulate in tumour tissues. By tracking and phenotypic profiling of LD hi cells, we find that LD hi CD19 + , LD hi CD11b + , and LD hi Ly6G + immune cell populations appear in the spleen, thymus, and tumour tissues in a syngeneic tumour model. Using a contact‐dependent reporter system, we discover a LD hi CCR7 hi immunosuppressive cell population that migrates from tumour tissues to the spleen and thymus. Hence, we engineered a family of chimeric antigen receptor‐modified macrophages (CAR‐Ms) that direct macrophages to CCR7‐positive cells and show that the cytosolic domain from Mer receptor tyrosine kinase (MerTK) triggers tumour cell cytotoxicity by the CAR‐Ms. In vivo , CCR7‐targeted CAR‐Ms suppressed tumour growth and prolonged survival by preventing metastasis and by inducing systemic anti‐tumour immunity through retarding the migration of LD hi CCR7 hi immunosuppressive cells from tumour tissues to distal immune organs, indicating an important role for CCR7 in tumour cell‐induced immune tolerance. © 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Topics & Concepts

ImmunologyImmunityAntigenReceptorMedicineImmune systemInternal medicineCancer Immunotherapy and BiomarkersImmune Cell Function and InteractionImmunotherapy and Immune Responses
Chimeric antigen receptor‐modified macrophages trigger systemic anti‐tumour immunity | Litcius